Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Skin test could reveal Parkinson's progression

NCT ID NCT06621602

Knowledge-focused Sponsor: CND Life Sciences Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study uses a small skin sample to measure levels of a protein linked to Parkinson's disease and REM sleep behavior disorder. Researchers will follow 100 participants for 18 months to see if changes in the protein match disease progression. The goal is to develop a simple biomarker test to track the disease.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If successful, this could lead to a simple skin test to monitor Parkinson's disease progression and help develop new treatments.
What could go wrong
This is an early observational study with only 100 participants, so results may not apply to everyone. The protein levels in skin may not reliably reflect brain changes.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 100 people

The number the study aims to enrol. It can still change while the study runs.

Started

Dec 2024

Expected to finish

Apr 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Subjects will be enrolled from 18 sites across the US from academic institutions and private clinics.

Ages

50 to 85 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Male and female 50 to 85 years of age 2. Clinical confirmed diagnosis of Parkinson's disease or REM Sleep Behavior Exclusion Criteria: 1. Clinical evidence of severe vascular disease (history of ulceration, poor wound healing or vascular claudication) 2. History of allergic reaction to Lidocaine for local anesthesia needed for skin biopsies 3. Use of blood thinners (Plavix or Aspirin used separately is allowed) 4. Significantly impaired wound healing or history of scarring or keloid formation

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Parkinson disease are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Parkinson disease REM sleep behavior disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Parkinson disease Rem behavior disorder

Contacts and locations

Locations

  • Atlanta NeuroScience Institute ANI

    Atlanta, Georgia, 30327, United States

  • Aventura Neurologic Associates, LLC

    Aventura, Florida, 33180, United States

  • Boston Neuro Research Center

    Boston, Massachusetts, 02747, United States

  • CND Life Sciences

    Scottsdale, Arizona, 85258, United States

  • Cedars Sinai

    Los Angeles, California, 90048, United States

  • MedStar Montgomery Medical Center

    Olney, Maryland, 20832, United States

  • Movement Disorders Center of Arizona

    Scottsdale, Arizona, 85258, United States

  • Neurology Multidisciplinary Clinic at Norton Healthcare

    Louisville, Kentucky, 40241, United States

  • Parkinson's Disease and Movement Disorders Center - Boca Raton

    Boca Raton, Florida, 33486, United States

  • Parkinson's Disease and Movement Disorders Center at KUMC

    Kansas City, Kansas, 66160, United States

  • Parkinson's Research Centers of America - Long Island

    Commack, New York, 11725, United States

  • Parkinson's Research Centers of America - Orange County

    Aliso Viejo, California, 92656, United States

  • Parkinson's Research Centers of America - Palo Alto

    Palo Alto, California, 94301, United States

  • The Medical University of South Carolina

    Charleston, South Carolina, 29403, United States

  • UT Health San Antonio

    San Antonio, Texas, 78229, United States

  • University of Colorado

    Aurora, Colorado, 80045, United States

  • University of Rochester

    Rochester, New York, 14618, United States

  • Veracity Neuroscience LLC

    Memphis, Tennessee, 38157, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.